Veraxa Biotech AG (VRXA)

Market Cap	51.70M -84.3%
Revenue (ttm)	n/a
Net Income	n/a
EPS	n/a
Shares Out	25.22M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,764,145
Open	1.765
Previous Close	1.725
Day's Range	1.765 - 2.420
52-Week Range	1.700 - 27.360
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About VRXA

Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation....

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2021
• Country: Germany
• Stock Exchange: NASDAQ
• Ticker Symbol: VRXA
• Website: https://www.veraxa.com

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jul 2, 2026

Data Sources Report a data error